

# Ursula Wiedermann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3018874/publications.pdf>

Version: 2024-02-01

168  
papers

4,850  
citations

93792

39  
h-index

150775

59  
g-index

185  
all docs

185  
docs citations

185  
times ranked

5332  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open, 2022, 7, 100361.	2.0	18
2	Autochthonous Human <i>Dirofilaria repens</i> Infection in Austria. Acta Parasitologica, 2022, 67, 1039-1043.	0.4	4
3	SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year. Frontiers in Medicine, 2022, 9, 822316.	1.2	2
4	Vaccine based on folded receptor binding domainâ€PreS fusion protein with potential to induce sterilizing immunity to SARSâ€CoVâ€2 variants. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2431-2445.	2.7	16
5	22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases. Annals of Oncology, 2022, 33, S11-S12.	0.6	0
6	Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model. Translational Oncology, 2022, 19, 101378.	1.7	5
7	Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines, 2022, 10, 759.	2.1	1
8	SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients â€ A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. Frontiers in Immunology, 2022, 13, .	2.2	24
9	<scp>NKG2A</scp>â€checkpoint inhibition and its blockade critically depends on peptides presented by its ligand <scp>HLAâ€E</scp>. Immunology, 2022, 166, 507-521.	2.0	15
10	Towards understanding vaccine hesitancy and vaccination refusal in Austria. Wiener Klinische Wochenschrift, 2021, 133, 703-713.	1.0	17
11	Isolate-Based Surveillance of <i>Bordetella pertussis</i>, Austria, 2018â€2020. Emerging Infectious Diseases, 2021, 27, 862-871.	2.0	3
12	Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacitiesâ€An Agent-Based Modeling Evaluation. Vaccines, 2021, 9, 434.	2.1	27
13	Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancerâ€Results from Phase Ib Trial IMU.ACS.001. Clinical Cancer Research, 2021, 27, 3649-3660.	3.2	23
14	The EFIS vaccination task force expert report. European Journal of Immunology, 2021, 51, 1023-1027.	1.6	1
15	Circulation of pertussis and poor protection against diphtheria among middle-aged adults in 18 European countries. Nature Communications, 2021, 12, 2871.	5.8	29
16	HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. Journal of Clinical Oncology, 2021, 39, e16065-e16065.	0.8	4
17	Validation of a novel FRET real-time PCR assay for simultaneous quantitative detection and discrimination of human Plasmodium parasites. PLoS ONE, 2021, 16, e0252887.	1.1	7
18	Immunologically relevant aspects of the new COVID-19 vaccinesâ€an Ã–GAIÃ(Austrian Society for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Allergo Journal International, 2021, 30, 155-168.	0.9	6

#	ARTICLE	IF	CITATIONS
19	P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. <i>Annals of Oncology</i> , 2021, 32, S154.	0.6	1
20	Abstract CT107: A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSION METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION. <i>Cancer Research</i> , 2021, 81, CT107-CT107.	0.4	4
21	Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults. <i>Communications Medicine</i> , 2021, 1, .	1.9	19
22	Answers to burning questions for clinical allergologists related to the new COVID-19 vaccines. <i>Allergo Journal International</i> , 2021, 30, 169-175.	0.9	5
23	Emerging targets for anticancer vaccination: PD-1. <i>ESMO Open</i> , 2021, 6, 100278.	2.0	14
24	Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments. <i>Vaccine</i> , 2021, 39, 7375-7378.	1.7	7
25	Machine Learning-Empowered FTIR Spectroscopy Serum Analysis Stratifies Healthy, Allergic, and SIT-Treated Mice and Humans. <i>Biomolecules</i> , 2020, 10, 1058.	1.8	11
26	Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. <i>Vaccines</i> , 2020, 8, 719.	2.1	4
27	A novel 5-Plex qPCR-HRM assay detecting human diarrheal parasites. <i>Gut Pathogens</i> , 2020, 12, 27.	1.6	7
28	Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination. <i>Frontiers in Immunology</i> , 2020, 11, 860.	2.2	23
29	A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 895.	2.2	18
30	Pre- and Neonatal Imprinting on Immunological Homeostasis and Epithelial Barrier Integrity by Escherichia coli Nissle 1917 Prevents Allergic Poly-Sensitization in Mice. <i>Frontiers in Immunology</i> , 2020, 11, 612775.	2.2	5
31	Reduction of Allergic Lung Disease by Mucosal Application of Toxoplasma gondii-Derived Molecules: Possible Role of Carbohydrates. <i>Frontiers in Immunology</i> , 2020, 11, 612766.	2.2	4
32	Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept. <i>Annals of Oncology</i> , 2020, 31, 319-321.	0.6	6
33	Abstract 3151: Active immunization with PD1-derived mimotope-Combination immunotherapy against Her-2/neu-expressing tumors. , 2020, , .		0
34	Editorial: Challenges in Vaccinology. <i>Frontiers in Immunology</i> , 2020, 11, 632537.	2.2	2
35	Medical students' knowledge and attitudes regarding vaccination against measles, influenza and HPV. An international multicenter study. <i>Journal of Preventive Medicine and Hygiene</i> , 2020, 61, E181-E185.	0.9	1
36	Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. <i>Scientific Reports</i> , 2019, 9, 11472.	1.6	109

#	ARTICLE	IF	CITATIONS
37	Active immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumour effect against HER-2/neu-expressing tumours. <i>Annals of Oncology</i> , 2019, 30, v480.	0.6	0
38	Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer. <i>Annals of Oncology</i> , 2019, 30, v495-v496.	0.6	3
39	Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers. <i>Annals of Oncology</i> , 2019, 30, v746.	0.6	0
40	Vaccination of healthcare personnel in Europe: Update to current policies. <i>Vaccine</i> , 2019, 37, 7576-7584.	1.7	86
41	Germ-Free Mice Exhibit Mast Cells With Impaired Functionality and Gut Homing and Do Not Develop Food Allergy. <i>Frontiers in Immunology</i> , 2019, 10, 205.	2.2	43
42	The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4391-4404.	2.4	5
43	Phase 2 clinical results: Chikungunya vaccine based on measles vector (MV-CHIK) induces humoral and cellular responses in the presence of pre-existing anti measles immunity. <i>International Journal of Infectious Diseases</i> , 2019, 79, 118.	1.5	3
44	Routine Adult Vaccines. , 2019, , 75-87.		0
45	Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. <i>PLoS ONE</i> , 2019, 14, e0210081.	1.1	25
46	E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization. <i>Mucosal Immunology</i> , 2019, 12, 132-144.	2.7	28
47	A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4030-4030.	0.8	2
48	Mandatory vaccination: suited to enhance vaccination coverage in Europe?. <i>Eurosurveillance</i> , 2019, 24, .	3.9	21
49	Reiseimpfungen mit spezieller Indikation: Gelbfieber, Tollwut, Japanische Enzephalitis, Typhus, Meningokokken. <i>Intrinsic Activity</i> , 2019, 7, e1.	0.0	0
50	A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS176-TPS176.	0.8	1
51	Abstract CT059: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach. , 2019, , .		0
52	Abstract 4110: Identification of PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity: New strategy for cancer immunotherapy. , 2019, , .		0
53	Abstract CT059: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach. , 2019, , .		0
54	Abstract 4110: Identification of PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity: New strategy for cancer immunotherapy. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Prophylactic and therapeutic inhibition of allergic airway inflammation by probiotic <i>Escherichia coli</i> O83. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1987-1990.e7.	1.5	10
56	Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2718-2727.	6.3	116
57	Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. <i>Scientific Reports</i> , 2018, 8, 9825.	1.6	72
58	Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 bias. <i>Vaccine</i> , 2018, 36, 2816-2824.	1.7	12
59	Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. <i>BMC Cancer</i> , 2017, 17, 118.	1.1	27
60	Murine models for mucosal tolerance in allergy. <i>Seminars in Immunology</i> , 2017, 30, 12-27.	2.7	12
61	<i>Toxoplasma gondii</i> tachyzoite-extract acts as a potent immunomodulator against allergic sensitization and airway inflammation. <i>Scientific Reports</i> , 2017, 7, 15211.	1.6	14
62	Universal Mass Vaccination Against Rotavirus: Indirect Effects on Rotavirus Infections in Neonates and Unvaccinated Young Infants Not Eligible for Vaccination. <i>Journal of Infectious Diseases</i> , 2016, 214, 546-555.	1.9	19
63	Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine. <i>Vaccine</i> , 2016, 34, 2027-2034.	1.7	20
64	Primary vaccine failure to routine vaccines: Why and what to do?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 239-243.	1.4	110
65	Oocyst-Derived Extract of <i>Toxoplasma Gondii</i> Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy. <i>PLoS ONE</i> , 2016, 11, e0155081.	1.1	8
66	Paediatricians require more information before they routinely co-administer the meningococcal B vaccine with routine infant vaccines. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2015, 104, e439-47.	0.7	4
67	Prime-Boost Vaccination with <i>Toxoplasma</i> Lysate Antigen, but Not with a Mixture of Recombinant Protein Antigens, Leads to Reduction of Brain Cyst Formation in BALB/c Mice. <i>PLoS ONE</i> , 2015, 10, e0126334.	1.1	21
68	Genetic Variation of <i>Bordetella pertussis</i> in Austria. <i>PLoS ONE</i> , 2015, 10, e0132623.	1.1	17
69	The Role of Alveolar Epithelial Type II-Like Cells in Uptake of Structurally Different Antigens and in Polarisation of Local Immune Responses. <i>PLoS ONE</i> , 2015, 10, e0124777.	1.1	6
70	Allergy and worms: let's bring back old friends?. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 382-391.	0.5	4
71	Allergen hybrids – next generation vaccines for allergic pollen immunotherapy. <i>Clinical and Experimental Allergy</i> , 2014, 44, 438-449.	1.4	14
72	Characteristics of invasive pneumococcal disease in hospitalized children in Austria. <i>European Journal of Pediatrics</i> , 2014, 173, 469-476.	1.3	8

#	ARTICLE	IF	CITATIONS
73	Reaktionen und Nebenwirkungen nach Impfungen: Erl�uterungen und Definitionen in Erg�nzung zum �sterreichischen Impfplan. <i>Intrinsic Activity</i> , 2014, 2, e2.	0.0	1
74	Impfungen f�r MitarbeiterInnen des Gesundheitswesens: Empfehlungen als Erweiterung des �sterreichischen Impfplans. <i>Intrinsic Activity</i> , 2014, 2, e5.	0.0	0
75	Neonatal colonization of germ-free mice with <i>Bifidobacterium longum</i> prevents allergic sensitization to major birch pollen allergen Bet v 1. <i>Vaccine</i> , 2013, 31, 5405-5412.	1.7	36
76	Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 1-12.	1.1	33
77	Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination. <i>Vaccine</i> , 2013, 31, 1293-1297.	1.7	43
78	Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy. <i>Immunobiology</i> , 2013, 218, 884-891.	0.8	37
79	Tick-Borne Encephalitis (TBE) and Hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination with Involvement of Regulatory T and B Cells and IL-10. <i>Journal of Immunology</i> , 2013, 191, 2426-2436.	0.4	48
80	<i>Oesophagostomum dentatum</i> Extract Modulates T Cell-Dependent Immune Responses to Bystander Antigens and Prevents the Development of Allergy in Mice. <i>PLoS ONE</i> , 2013, 8, e67544.	1.1	23
81	Traveler�s Diarrhea. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 691-706.	1.9	40
82	Prevention of Birch Pollen-Related Food Allergy by Mucosal Treatment with Multi-Allergen-Chimers in Mice. <i>PLoS ONE</i> , 2012, 7, e39409.	1.1	10
83	Perinatal Maternal Administration of <i>Lactobacillus paracasei</i> NCC 2461 Prevents Allergic Inflammation in a Mouse Model of Birch Pollen Allergy. <i>PLoS ONE</i> , 2012, 7, e40271.	1.1	37
84	Thioredoxin from the Indianmeal Moth <i>Plodia interpunctella</i> : Cloning and Test of the Allergenic Potential in Mice. <i>PLoS ONE</i> , 2012, 7, e42026.	1.1	12
85	Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization. <i>Vaccine</i> , 2011, 29, 1981-1990.	1.7	38
86	Persistence of antibodies in 4�8 year old Austrian children after vaccination with hexavalent DTaP�HBV�IPV/Hib and MMR vaccines. <i>Vaccine</i> , 2011, 29, 5130-5136.	1.7	13
87	Neonatal colonization of mice with <i>Lactobacillus plantarum</i> producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 368-375.	2.7	43
88	Sensitivity of <i>Plasmodium vivax</i> to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 20-25.	1.0	9
89	Tetanus Immunity in Neonates in a Developed Country. <i>Neonatology</i> , 2011, 100, 52-56.	0.9	4
90	High-Affinity IgE Receptors on Dendritic Cells Exacerbate Th2-Dependent Inflammation. <i>Journal of Immunology</i> , 2011, 187, 164-171.	0.4	71

#	ARTICLE	IF	CITATIONS
91	Synergism between mefloquine and artemisinin and its enhancement by retinol in <i>Plasmodium falciparum</i> in vitro. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 57-60.	1.0	7
92	A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 673-683.	1.1	99
93	Tick borne encephalitis TBE " Vaccination in non-endemic countries. <i>Travel Medicine and Infectious Disease</i> , 2010, 8, 251-256.	1.5	10
94	Hitting the Mucosal Road in Tolerance Induction. <i>Nestle Nutrition Workshop Series Paediatric Programme</i> , 2009, 64, 63-74.	1.5	2
95	Immunoregulation by <i>Toxoplasma gondii</i> infection prevents allergic immune responses in mice. <i>International Journal for Parasitology</i> , 2009, 39, 465-472.	1.3	35
96	Travellers' diarrhoea " pros and cons of different prophylactic measures. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 13-18.	1.0	9
97	Early Dietary Influence on Later Immunocompetence. <i>Nutrition Reviews</i> , 2009, 54, S23-S30.	2.6	12
98	Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. <i>Vaccine</i> , 2009, 27, 197-204.	1.7	25
99	Booster vaccinations against tick-borne encephalitis: 6 Years follow-up indicates long-term protection. <i>Vaccine</i> , 2009, 27, 7027-7030.	1.7	36
100	Immunoregulation by microbes and parasites in the control of allergy and autoimmunity. , 2009, , 45-75.		3
101	Susceptibility to nasal and oral tolerance induction to the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora. <i>Immunology Letters</i> , 2008, 117, 50-56.	1.1	20
102	Pretravel Consultation: Rapid Dipstick Test as a Decision Guidance for the Application of Tetanus Booster Vaccinations. <i>Journal of Travel Medicine</i> , 2008, 15, 437-441.	1.4	23
103	Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 518-526.	2.7	45
104	Airway inflammation induced after allergic polysensitization can be prevented by mucosal but not by systemic administration of poly-peptides. <i>Clinical and Experimental Allergy</i> , 2008, 38, 1192-1202.	1.4	16
105	Seroprotection 4 years following booster vaccination against tick-borne encephalitis. <i>International Journal of Medical Microbiology</i> , 2008, 298, 305-308.	1.5	5
106	Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine. <i>Clinical Cancer Research</i> , 2008, 14, 8178-8183.	3.2	19
107	Lactic acid bacteria as novel adjuvant systems for prevention and treatment of atopic diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2008, 8, 557-564.	1.1	36
108	Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. <i>Vaccine</i> , 2007, 25, 927-931.	1.7	50



#	ARTICLE	IF	CITATIONS
109	Antibody persistence following booster vaccination against tick-borne encephalitis: 3-Year post-booster follow-up. <i>Vaccine</i> , 2007, 25, 5097-5101.	1.7	45
110	Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. <i>Vaccine</i> , 2007, 25, 8395-8404.	1.7	26
111	A recombinant allergen chimera as novel mucosal vaccine candidate for prevention of multi-sensitivities. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 33-41.	2.7	39
112	The European LABDEL project and its relevance to the prevention and treatment of allergies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1237-1242.	2.7	18
113	New allergy intervention strategies: hitting the mucosal road. <i>Clinical and Experimental Allergy</i> , 2007, 37, 473-475.	1.4	4
114	Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 29-38.	1.1	25
115	The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice.. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 173-180.	2.7	41
116	Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 812-819.	2.7	101
117	Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 280-285.	1.0	20
118	Vaccines against traveler's diarrhoea and rotavirus disease – a review. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 2-8.	1.0	13
119	Epitope-Specific Antibody Response to Mel-CAM Induced by Mimotope Immunization. <i>Journal of Investigative Dermatology</i> , 2005, 124, 125-131.	0.3	11
120	Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. <i>International Journal of Cancer</i> , 2005, 114, 426-432.	2.3	28
121	Prophylaxis and Therapy of Allergy by Mucosal Tolerance Induction with Recombinant Allergens or Allergen Constructs. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 577-583.	3.1	26
122	Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro. <i>Journal of Immunology</i> , 2005, 174, 976-982.	0.4	46
123	A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1010-1016.	1.5	83
124	Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 370-376.	1.5	39
125	Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 7. <i>Journal of Immunology</i> , 2004, 172, 5684-5692.	0.4	62
126	Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. <i>Clinical and Experimental Allergy</i> , 2004, 34, 1525-1533.	1.4	82



#	ARTICLE	IF	CITATIONS
127	Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy. <i>Clinical and Experimental Immunology</i> , 2004, 137, 12-18.	1.1	39
128	Expression of the B subunit of the heat-labile enterotoxin of <i>Escherichia coli</i> in tobacco mosaic virus-infected <i>Nicotiana benthamiana</i> plants and its characterization as mucosal immunogen and adjuvant. <i>Journal of Immunological Methods</i> , 2004, 287, 203-215.	0.6	35
129	Potential and Opportunities for Use of Recombinant Lactic Acid Bacteria in Human Health. <i>Advances in Applied Microbiology</i> , 2004, 56, 1-64.	1.3	67
130	Animal models of type I allergy using recombinant allergens. <i>Methods</i> , 2004, 32, 271-280.	1.9	51
131	Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. <i>International Journal of Cancer</i> , 2003, 107, 976-983.	2.3	49
132	Vitamin A deficiency leads to severe functional disturbance of the intestinal epithelium enzymes associated with diarrhoea and increased bacterial translocation in gnotobiotic rats. <i>Microbes and Infection</i> , 2003, 5, 405-411.	1.0	28
133	Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of <i>Vespula vulgaris</i> venom, in a murine model of wasp venom allergy. <i>Immunology</i> , 2003, 110, 376-385.	2.0	42
134	Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice. <i>Clinical and Experimental Immunology</i> , 2003, 133, 170-176.	1.1	29
135	Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. <i>Vaccine</i> , 2003, 22, 87-95.	1.7	114
136	Mucosal Immunity - Mucosal Tolerance. , 2003, 82, 11-24.		11
137	Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. <i>Clinical and Experimental Allergy</i> , 2002, 32, 30-36.	1.4	47
138	Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. <i>Immunology</i> , 2002, 107, 523-529.	2.0	40
139	Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. <i>Clinical and Experimental Allergy</i> , 2002, 32, 1583-1588.	1.4	36
140	Edible genetically modified microorganisms and plants for improved health. <i>Current Opinion in Biotechnology</i> , 2001, 12, 510-515.	3.3	26
141	Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice. <i>International Archives of Allergy and Immunology</i> , 2001, 126, 68-77.	0.9	55
142	Rapid Production of Recombinant Allergens in <i>Nicotiana benthamiana</i> and Their Impact on Diagnosis and Therapy. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 48-50.	0.9	24
143	Mucosal Tolerance Induction with Hypoallergenic Molecules in a Murine Model of Allergic Asthma. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 391-394.	0.9	22
144	IgE Mimotopes of Birch Pollen Allergen Bet v 1 Induce Blocking IgG in Mice. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 395-397.	0.9	14

#	ARTICLE	IF	CITATIONS
145	Monovalent fusion proteins of immunoglobulin E mimotopes are safe for therapy of type I allergy. <i>FASEB Journal</i> , 2001, 15, 2524-2526.	0.2	26
146	Rapid production of the major birch pollen allergen Bet v 1 in <i>Nicotiana benthamiana</i> plants and its immunological in vitro and in vivo characterization. <i>FASEB Journal</i> , 2000, 14, 1279-1288.	0.2	42
147	Different HBs Antibody versus Lymphoproliferative Responses after Application of a Monovalent (Hepatitis B) or Combined (Hepatitis A + Hepatitis B) Vaccine. <i>International Archives of Allergy and Immunology</i> , 2000, 123, 349-353.	0.9	2
148	Rapid production of the major birch pollen allergen Bet v 1 in <i>Nicotiana benthamiana</i> plants and its immunological in vitro and in vivo characterization. <i>FASEB Journal</i> , 2000, 14, 1279-1288.	0.2	40
149	Allergen mimotopes in food enhance type I allergic reactions in mice. <i>FASEB Journal</i> , 1999, 13, 1586-1592.	0.2	63
150	Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. <i>International Immunology</i> , 1999, 11, 1717-1724.	1.8	31
151	Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. <i>International Immunology</i> , 1999, 11, 1131-1138.	1.8	37
152	Modulation of an Allergic Immune Response via the Mucosal Route in a Murine Model of Inhalative Type I Allergy. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 129-132.	0.9	9
153	Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 1015-1023.	1.5	61
154	Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen, in a murine model of type I allergy. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, 1202-1210.	1.5	66
155	Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen. <i>Clinical and Experimental Immunology</i> , 1998, 111, 144-151.	1.1	50
156	Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 679-686.	1.5	119
157	Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phi p 1, a major grass pollen allergen. <i>Clinical and Experimental Allergy</i> , 1997, 27, 1007-1015.	1.4	288
158	Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. <i>Clinical and Experimental Immunology</i> , 1997, 107, 536-541.	1.1	63
159	Effects of Breastfeeding on the Baby and on Its Immune System. <i>Food and Nutrition Bulletin</i> , 1996, 17, 1-5.	0.5	7
160	VITAMIN A DEFICIENCY INCREASES INFLAMMATORY RESPONSES. <i>Scandinavian Journal of Immunology</i> , 1996, 44, 578-584.	1.3	82
161	Vitamin A deficiency predisposes to <i>Staphylococcus aureus</i> infection. <i>Infection and Immunity</i> , 1996, 64, 209-214.	1.0	64
162	Increased translocation of <i>Escherichia coli</i> and development of arthritis in vitamin A-deficient rats. <i>Infection and Immunity</i> , 1995, 63, 3062-3068.	1.0	29

#	ARTICLE	IF	CITATIONS
163	T-cell-independent and T-cell-dependent IgE responses to the nematode <i>Nippostrongylus brasiliensis</i> : comparison of serum IgE and mast-cell-bound IgE. <i>Immunology</i> , 1995, 86, 351-5.	2.0	8
164	Impaired mucosal immune response in vitamin A deficient rats immunized with oral cholera vaccine. <i>Advances in Experimental Medicine and Biology</i> , 1995, 371B, 1629-31.	0.8	3
165	Antibody Response in Bronchoalveolar Lavage and Bile in Rats after Aerosol Immunisation with an &lt;i>Escherichia coli</i> Strain Producing Ovalbumin. <i>International Archives of Allergy and Immunology</i> , 1993, 101, 254-259.	0.9	2
166	Sensitization and development of tolerance via the gut. <i>Pediatric Allergy and Immunology</i> , 1993, 4, 16-20.	1.1	10
167	Impaired mucosal antibody response to cholera toxin in vitamin A-deficient rats immunized with oral cholera vaccine. <i>Infection and Immunity</i> , 1993, 61, 3952-3957.	1.0	69
168	Aberrant T-cell function in vitro and impaired T-cell dependent antibody response in vivo in vitamin A-deficient rats. <i>Immunology</i> , 1993, 80, 581-6.	2.0	69